Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction

Clinical Toxicology

Volumn 47, Issue 1, 2009, Pages 14-23

  Wood, David M ^a   Dargan, Paul I ^a   Hoffman, Robert S ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b NEW YORK CITY POISON CONTROL CENTER   (United States)

Author keywords

Cocaine; ECG changes; Management; Poisoning management; Toxicology

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 5 FLUORO 2 METHOXY 1H INDOLE 3 CARBOXYLIC ACID 1 [2 (METHYLSULFONAMIDO)ETHYL] 4 PIPERIDINYLMETHYL ESTER; ANTIARRHYTHMIC AGENT; BENZOTHIAZEPINE DERIVATIVE; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; COCAINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; ECOPIPAM; FLECAINIDE; ION CHANNEL; LIDOCAINE; MAGNESIUM; MORACIZINE; NIFEDIPINE; PHENYLALKYLAMINE; SODIUM CHANNEL; VERAPAMIL; POTASSIUM CHANNEL;

BRUGADA SYNDROME; DEFIBRILLATOR; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; MUSCLE ACTION POTENTIAL; NONHUMAN; QRS COMPLEX; REVIEW; SIDE EFFECT; SUDDEN DEATH; ACTION POTENTIAL; ANIMAL; CHEMICALLY INDUCED DISORDER; COCAINE DEPENDENCE; HEART MUSCLE; LONG QT SYNDROME; METABOLISM;

ANIMALIA;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; COCAINE; COCAINE-RELATED DISORDERS; HUMANS; LIDOCAINE; LONG QT SYNDROME; MYOCARDIUM; POTASSIUM CHANNELS; SODIUM BICARBONATE; SODIUM CHANNELS;

EID: 59649097134     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650802339373     Document Type: Review

References (116)

1. United Nations Office on Drugs and Crime. World Drug Report 2007. http://www.unodc.org/pdf/research/wdr07/WDR-2007.pdf. Accessed 5 June 2008.
2. Schwartz AB, Janzen D, Jones RT, Boyle W. Electrocardiographic and hemodynamic effects of intravenous cocaine in awake and anesthetized dogs. J Electrocardiol 1989; 22:159-166.
3. Matsuda Y, Masuda Y, Levy MN. The effects of cocaine and metanephrine on the cardiac responses to sympathetic nerve stimulation in dogs. Circ Res 1979; 45:180-187.
4. Catravas JD, Waters IW. Acute cocaine intoxication in the conscious dog: studies on the mechanism of lethality. J Pharmacol Exp Ther 1981; 217:350-356.
5. Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation 1992; 85:407-419.
6. Frishman WH, Del Vecchio A, Sanal S, Ismail A. Cardiovascular manifestations of substance abuse part 1: cocaine. Heart Dis 2003; 5:187-201.
7. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351-358.
8. Goldfrank LR, Hoffman RS. The cardiovascular effects of cocaine. Ann Emerg Med 1991; 20:165-175.
9. Young TW, Glauber JJ. Electrocardiographic changes resulting from acute cocaine intoxication. Am Heart J 1947; 34:272-279.
10. Orr D, Jones I. Anaesthesia for laryngoscopy: a comparison of the cardiovascular effects of cocaine and lignocaine. Anaesthesia 1968; 23:194-202.
11. Fischman MW, Schuster CR, Resnekov L, Shick JF, Krasnegor NA, Fennell W, Freedman DX. Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch Gen Psychiatry 1976; 33:983-989.
12. Isner JM, Estes NA 3rd, Thompson PD, Costanzo-Nordin MR, Subramanian R, Miller G, Katsas G, Sweeney K, Sturner WQ. Acute cardiac events temporally related to cocaine abuse. N Engl J Med 1986; 315:1438-1443.
13. Benchimol A, Bartall H, Desser KB. Accelerated ventricular rhythm and cocaine abuse. Ann Intern Med 1978; 88:519-520.
14. Nanji AA, Filipenko JD. Asystole and ventricular fibrillation associated with cocaine intoxication. Chest 1984; 85:132-133.
15. Mittleman RE, Wetli CV. Cocaine and sudden "natural" death. J Forensic Sci 1987; 32:11-19.
16. Kerns W 2nd, Garvey L, Owens J. Cocaine-induced wide complex dysrhythmia. J Emerg Med 1997; 15:321-329.
17. Petronis KR, Anthony JC. An epidemiologic investigation of marijuana- and cocaine-related palpitations. Drug Alcohol Depend 1989; 23:219-226.
18. Dressler FA, Malekzadeh S, Roberts WC. Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts. Am J Cardiol 1990; 65:303-308.
19. Tazelaar HD, Karch SB, Stephens BG, Billingham ME. Cocaine and the heart. Hum Pathol 1987; 18:195-199.
20. Virmani R, Robinowitz M, Smialek JE, Smyth DF. Cardiovascular effects of cocaine: an autopsy study of 40 patients. Am Heart J 1988; 115:1068-1076.
21. Kabas JS, Blanchard SM, Matsuyama Y, Long JD, Hoffman GW Jr, Ellinwood EH, Smith PK, Strauss HC. Cocaine-mediated impairment of cardiac conduction in the dog: a potential mechanism for sudden death after cocaine. J Pharmacol Exp Ther 1990; 252:185-191.
22. Jonsson S, O'Meara M, Young JB. Acute cocaine poisoning. Importance of treating seizures and acidosis. Am J Med 1983; 75:1061-1064.
23. Fischman MW, Schuster CR. Cocaine self-administration in humans. Fed Proc 1982; 41:241-246.
24. Fischman MW, Schuster CR, Hatano Y. A comparison of the subjective and cardiovascular effects of cocaine and lidocaine in humans. Pharmacol Biochem Behav 1983; 18:123-127.
25. Sherief HT, Carpentier RG. Electrophysiological mechanisms of cocaine-induced cardiac arrest. A possible cause of sudden cardiac death. J Electrocardiol 1991; 24:247-255.
26. Mittleman RE, Wetli CV. Death caused by recreational cocaine use. An update. JAMA 1984; 252:1889-1893.
27. Starmer CF, Grant AO, Strauss HC. Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics. Biophys J 1984; 46:15-27.
28. Crumb WJ Jr, Clarkson CW. Characterization of the sodium channel blocking properties of the major metabolites of cocaine in single cardiac myocytes. J Pharmacol Exp Ther 1992; 261:910-917.
29. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24:129-147.
30. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788.
31. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992; 327:227-233.
32. Xu YQ, Crumb WJ Jr, Clarkson CW. Cocaethylene, a metabolite of cocaine and ethanol, is a potent blocker of cardiac sodium channels. J Pharmacol Exp Ther 1994; 271:319-325.
33. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations, and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31:115-172.
34. Fenelon G, Uchoa J, Otobone JR, Reis M, do Amaral JL, de Paola AA. Characterization of the in vivo cardiac electrophysiologic effects of high-dose cocaine in closed-chest, anesthetized dogs with normal hearts. Arq Bras Cardiol 2003; 81:29-34.
35. Beckman KJ, Parker RB, Hariman RJ, Gallastegui JL, Javaid JI, Bauman JL. Hemodynamic and electrophysiological actions of cocaine. Effects of sodium bicarbonate as an antidote in dogs. Circulation 1991; 83:1799-1807.
36. Wilson LD, Jeromin J, Garvey L, Dorbandt A. Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse. Acad Emerg Med 2001; 8:211-222.
37. Parker RB, Perry GY, Horan LG, Flowers NC. Comparative effects of sodium bicarbonate and sodium chloride on reversing cocaine-induced changes in the electrocardiogram. J Cardiovasc Pharmacol 1999; 34:864-869.
38. Grawe JJ, Hariman RJ, Winecoff AP, Fischer JH, Bauman JL. Reversal of the electrocardiographic effects of cocaine by lidocaine. Part 2. Concentration-effect relationships. Pharmacotherapy 1994; 14:704-711.
39. Hondeghem LM, Katzung BG. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol 1984; 24:387-423.
40. Temesy-Armos PN, Fraker TD Jr, Brewster PS, Wilkerson RD. The effects of cocaine on cardiac electrophysiology in conscious, unsedated dogs. J Cardiovasc Pharmacol 1992; 19:883-891.
41. Erzouki HK, Baum I, Goldberg SR, Schindler CW. Comparison of the effects of cocaine and its metabolites on cardiovascular function in anesthetized rats. J Cardiovasc Pharmacol 1993; 22:557-563.
42. Crumb WJ Jr, Clarkson CW. The pH dependence of cocaine interaction with cardiac sodium channels. J Pharmacol Exp Ther 1995; 274:1228-1237.
43. Wang RY. pH-dependent cocaine-induced cardiotoxicity. Am J Emerg Med 1999; 17:364-369.
44. Lederer WJ, Tsien RW. Transient inward current underlying arrhythmogenic effects of cardiotonic steroids in Purkinje fibres. J Physiol 1976; 263:73-100.
45. Kurachi Y. The effects of intracellular protons on the electrical activity of single ventricular cells. Pflugers Arch 1982; 394:264-270.
46. Reber WR, Weingart R. Ungulate cardiac purkinje fibres: the influence of intracellular pH on the electrical cell-to-cell coupling. J Physiol 1982; 328:87-104.
47. Liu D, Hariman RJ, Bauman JL. Cocaine concentration-effect relationship in the presence and absence of lidocaine: evidence of competitive binding between cocaine and lidocaine. J Pharmacol Exp Ther 1996; 276:568-577.
48. Derlet RW, Albertson TE. Potentiation of cocaine toxicity with calcium channel blockers. Am J Emerg Med 1989; 7:464-468.
49. Heit J, Hoffman RS, Goldfrank LR. The effects of lidocaine pretreatment on cocaine neurotoxicity and lethality in mice. Acad Emerg Med 1994; 1:438-442.
50. Shih RD, Hollander JE, Burstein JL, Nelson LS, Hoffman RS, Quick AM. Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction. Ann Emerg Med 1995; 26:702-706.
51. Sasyniuk BI, Jhamandas V. Mechanism of reversal of toxic effects of amitriptyline on cardiac Purkinje fibers by sodium bicarbonate. J Pharmacol Exp Ther 1984; 231:387-394.
52. Bajaj AK, Woosley RL, Roden DM. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation 1989; 80:994-1002.
53. Greene SL, Dargan PI, Jones AL. Acute poisoning: understanding 90% of cases in a nutshell. Postgrad Med J 2005; 81:204-216.
54. Morganroth J, Horowitz LN. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984; 53:89B-94B.
55. Keyler DE, Pentel PR. Hypertonic sodium bicarbonate partially reverses QRS prolongation due to flecainide in rats. Life Sci 1989; 45:1575-1580.
56. Pentel PR, Fifield J, Salerno DM. Lack of effect of hypertonic sodium bicarbonate on QRS duration in patients taking therapeutic doses of class IC antiarrhythmic drugs. J Clin Pharmacol 1990; 30:789-794.
57. Winecoff AP, Hariman RJ, Grawe JJ, Wang Y, Bauman JL. Reversal of the electrocardiographic effects of cocaine by lidocaine. Part 1. Comparison with sodium bicarbonate and quinidine. Pharmacotherapy 1994; 14:698-703.
58. Shi B, Heavner JE, Liu J, Wang MJ, Lutherer LO, McIntyre DC, Reigel CE. Two genetically selected strains of rats exhibit hypersensitivity or resistance to cocaine-induced fatal arrhythmias. J Pharmacol Exp Ther 1999; 288:685-692.
59. Billman GE. The effect of adrenergic receptor antagonists on cocaine-induced ventricular fibrillation: alpha but not beta adrenergic receptor antagonists prevent malignant arrhythmias independent of heart rate. J Pharmacol Exp Ther 1994; 269:409-416.
60. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20:1391-1396.
61. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659-670.
62. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O'Brien RE, Schulze-Bahr E, Keating MT, Towbin JA, Wang Q. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392:293-296.
63. Bebarta VS, Summers S. Brugada electrocardiographic pattern induced by cocaine toxicity. Ann Emerg Med 2007; 49:827-829.
64. Ortega-Carnicer J, Bertos-Polo J, Gutierrez-Tirado C. Aborted sudden death, transient Brugada pattern, and wide QRS dysrrhythmias after massive cocaine ingestion. J Electrocardiol 200; 34:345-349.
65. Littmann L, Monroe MH, Svenson RH. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc 2000; 75:845-849.
66. Brugada P, Brugada R, Brugada J, Geelen P. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am J Cardiol 1999; 83:98D-100D.
67. Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. J Electrocardiol 2000; 33(Suppl):41-47.
68. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80:795-803.
69. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996; 94:1996-2012.
70. Priori SG, Corr PB. Mechanisms underlying early and delayed after-depolarizations induced by catecholamines. Am J Physiol 1990; 258:H1796-H1805.
71. O'Leary ME. Inhibition of human ether-a-go-go potassium channels by cocaine. Mol Pharmacol 2001; 59:269-277.
72. Ferreira S, Crumb WJ, Carlton CG, Clarkson CW. Effects of cocaine and its major metabolites on the HERG-encoded potassium channel. J Pharmacol Exp Ther 2001; 299:220-226.
73. Toennes SW, Fandino AS, Kauert G. Gas chromatographic-mass spectrometric detection of anhydroecgonine methyl ester (methylecgonidine) in human serum as evidence of recent smoking of crack. J Chromatogr B Biomed Sci Appl 1999; 735:127-132.
74. Bailey DN. Serial plasma concentrations of cocaethylene, cocaine, and ethanol in trauma victims. J Anal Toxicol 1993; 17:79-83.
75. Grant BF, Harford TC. Concurrent and simultaneous use of alcohol with cocaine: results of national survey. Drug Alcohol Depend 1990; 25:97-104.
76. Kimura S, Bassett AL, Xi H, Myerburg RJ. Early afterdepolarizations and triggered activity induced by cocaine: a possible mechanism of cocaine arrhythmogenesis. Circulation 1992; 85:2227-2235.
77. Clarkson CW, Xu YQ, Chang C, Follmer CH. Analysis of the ionic basis for cocaine's biphasic effect on action potential duration in guinea-pig ventricular myocytes. J Mol Cell Cardiol 1996; 28:667-678.
78. Magnano AR, Talathoti NB, Hallur R, Jurus DT, Dizon J, Holleran S, Bloomfield DM, Collins E, Garan H. Effect of acute cocaine administration on the QTc interval of habitual users. Am J Cardiol 2006; 97:1244-1246.
79. Haigney MC, Alam S, Tebo S, Marhefka G, Elkashef A, Kahn R, Chiang CN, Vocci F, Cantilena L. Intravenous cocaine and QT variability. J Cardiovasc Electrophysiol 2006; 17:610-616.
80. Schrem SS, Belsky P, Schwartzman D, Slater W. Cocaine-induced torsades de pointes in a patient with the idiopathic long QT syndrome. Am Heart J 1990; 120:980-984.
81. Singh N, Singh HK, Singh PP, Khan IA. Cocaine-induced torsades de pointes in idiopathic long Q-T syndrome. Am J Ther 2001; 8:299-302.
82. Taylor D, Parish D, Thompson L, Cavaliere M. Cocaine induced prolongation of the QT interval. Emerg Med J 2004; 21:252-253.
83. Perera R, Kraebber A, Schwartz MJ. Prolonged QT interval and cocaine use. J Electrocardiol 1997; 30:337-339.
84. Chakko S, Sepulveda S, Kessler KM, Sotomayor MC, Mash DC, Prineas RJ, Myerburg RJ. Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse). Am J Cardiol 1994; 74:710-713.
85. Hoffman RS, Smilkstein MJ, Goldfrank LR. Whole bowel irrigation and the cocaine body-packer: a new approach to a common problem. Am J Emerg Med 1990; 8:523-527.
86. Tzivoni D, Keren A, Cohen AM, Loebel H, Zahavi I, Chenzbraun A, Stern S. Magnesium therapy for torsades de pointes. Am J Cardiol 1984; 53:528-530.
87. Takanaka C, Ogunyankin KO, Sarma JS, Singh BN. Antiarrhythmic and arrhythmogenic actions of varying levels of extracellular magnesium: possible cellular basis for the differences in the efficacy of magnesium and lidocaine in torsade de pointes. J Cardiovasc Pharmacol Ther 1997; 2:125-134.
88. Bauman JL, DiDomenico RJ. Cocaine-induced channelopathies: emerging evidence on the multiple mechanisms of sudden death. J Cardiovasc Pharmacol Ther 2002; 7:195-202.
89. Khan IA, Win MT, Bali AJ, Vasavada BC, Sacchi TJ. Torsades de pointes: a case with multiple variables. Am J Emerg Med 1999; 17:80-85.
90. Billman GE. Mechanisms responsible for the cardiotoxic effects of cocaine. FASEB J 1990; 4:2469-2475.
91. Premkumar LS. Selective potentiation of L-type calcium channel currents by cocaine in cardiac myocytes. Mol Pharmacol 1999; 56:1138-1142.
92. Perreault CL, Hague NL, Ransil BJ, Morgan JP. The effects of cocaine on intracellular Ca2+ handling and myofilament Ca2+ responsiveness of ferret ventricular myocardium. Br J Pharmacol 1990; 101:679-685.
93. Levy MN. Role of calcium in arrhythmogenesis. Circulation 1989; 80:IV23-IV30.
94. Billman GE. Effect of calcium channel antagonists on susceptibility to sudden cardiac death: protection from ventricular fibrillation. J Pharmacol Exp Ther 1989; 248:1334-1342.
95. Trouve R, Nahas G. Nitrendipine: an antidote to cardiac and lethal toxicity of cocaine. Proc Soc Exp Biol Med 1986; 183:392-397.
96. Billman GE. Effect of calcium channel antagonists on cocaine-induced malignant arrhythmias: protection against ventricular fibrillation. J Pharmacol Exp Ther 1993; 266:407-416.
97. Billman GE, Hoskins RS. Cocaine-induced ventricular fibrillation: protection afforded by the calcium antagonist verapamil. FASEB J 1988; 2:2990-2995.
98. Kanani PM, Guse PA, Smith WM, Barnett A, Ellinwood EH. Acute deleterious effects of cocaine on cardiac conduction, hemodynamics, and ventricular fibrillation threshold: effects of interaction with a selective dopamine D1 antagonist SCH 39166. J Cardiovasc Pharmacol 1998; 32:42-48.
99. Ohuoha DC, Schindler CW, Rothman RB. Serotonin-4 receptor antagonists reverse cocaine-induced cardiac arrhythmia. Life Sci 1998; 63:1673-1678.
100. Coleman DL, Ross TF, Naughton JL. Myocardial ischemia and infarction related to recreational cocaine use. West J Med 1982;136:444-446.
101. Mittleman MA, Mintzer D, Maclure M, Tofler GH, Sherwood JB, Muller JE. Triggering of myocardial infarction by cocaine. Circulation 1999; 99:2737-2741.
102. Moliterno DJ, Willard JE, Lange RA, Negus BH, Boehrer JD, Glamann DB, Landau C, Rossen JD, Winniford MD, Hillis LD. Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. N Engl J Med 1994; 330:454-459.
103. Mo W, Singh AK, Arruda JA, Dunea G. Role of nitric oxide in cocaine-induced acute hypertension. Am J Hypertens 1998; 11:708-714.
104. He J, Yang S, Zhang L. Effects of cocaine on nitric oxide production in bovine coronary artery endothelial cells. J Pharmacol Exp Ther 2005; 314:980-986.
105. Wilbert-Lampen U, Seliger C, Zilker T, Arendt RM. Cocaine increases the endothelial release of immunoreactive endothelin and its concentrations in human plasma and urine: reversal by coincubation with sigma-receptor antagonists. Circulation 1998; 98:385-390.
106. Majid PA, Cheirif JB, Rokey R, Sanders WE, Patel B, Zimmerman JL, Dellinger RP. Does cocaine cause coronary vasospasm in chronic cocaine abusers? A study of coronary and systemic hemodynamics. Clin Cardiol 1992; 15:253-258.
107. Zurbano MJ, Heras M, Rigol M, Roig E, Epelde F, Miranda F, Sanz G, Escolar G, Ordinas A. Cocaine administration enhances platelet reactivity to subendothelial components: studies in a pig model. Eur J Clin Invest 1997; 27:116-120.
108. Pitts WR, Lange RA, Cigarroa JE, Hillis LD. Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management. Prog Cardiovasc Dis 1997; 40:65-76.
109. Sadanaga T, Ogawa S. Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent. J Am Coll Cardiol 1994; 23:1378-1381.
110. Roldan CA, Aliabadi D, Crawford MH. Prevalence of heart disease in asymptomatic chronic cocaine users. Cardiology 2001; 95:25-30.
111. Patrizi R, Pasceri V, Sciahbasi A, Summaria F, Rosano GM, Lioy E. Evidence of cocaine-related coronary atherosclerosis in young patients with myocardial infarction. J Am Coll Cardiol 2006; 47:2120-2122.
112. Meltser H, Bhakta D, Kalaria V. Multivessel coronary thrombosis secondary to cocaine use successfully treated with multivessel primary angioplasty. Int J Cardiovasc Intervent 2004; 6:39-42.
113. Kolodgie FD, Wilson PS, Cornhill JF, Herderick EE, Mergner WJ, Virmani R. Increased prevalence of aortic fatty streaks in cholesterol-fed rabbits administered intravenous cocaine: the role of vascular endothelium. Toxicol Pathol 1993; 21:425-435.
114. Núñez BD, Miao L, Klein MA, Núñez MM, Travers KE, Ross JN, Carrozza JP Jr, Morgan JP. Acute and chronic cocaine exposure can produce myocardial ischemia and infarction in Yucatan swine. J Cardiovasc Pharmacol 1997; 29:145-155.
115. Pletcher MJ, Kiefe CI, Sidney S, Carr JJ, Lewis CE, Hulley SB. Cocaine and coronary calcification in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am Heart J 2005; 150:921-926.
116. Flores ED, Lange RA, Cigarroa RG, Hillis LD. Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: enhanced vasoconstriction at sites of significant stenoses. J Am Coll Cardiol 1990; 16:74-79.